Oncology the focus for big pharma catalysts
The fourth quarter will see key immunotherapy data from Astrazeneca and Merck, while full details on Glaxo's anaemia pill, daprodustat, are expected.
Theravance fails its first big test
A flop for the gut-selective Jak inhibitor izencitinib makes a Johnson & Johnson opt-in look unlikely.
Go or no go? Ardelyx and Chemocentryx among those waiting FDA decisions
Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
Go or no go? The FDA plays hardball
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
AASLD 2020 – Nash updates from Novo and Inventiva in focus
At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.
